Downloads: 24
Research Paper | Diabetology | Volume 12 Issue 8, August 2023 | Pages: 2350 - 2355 | India
A Comparative Retrospective Study of Vildagliptin 100mg SR OD and Sitagliptin 100 mg in Subjects with Type 2 Diabetes Mellitus
Abstract: Diabetes mellitus is a chronic metabolic disorder characterized by insufficient insulin secretion from ? - cells of pancreatic islet leads to increased blood glucose level and cause damage to the cardiovascular system, kidneys, eyes, and nerves. Dipeptidyl peptidase 4 (DPP - 4) inhibitors are the drugs that inhibit degradations of incretin hormones which enhance insulin secretion. Vildagliptin and Sitagliptin are oral DDP - 4 inhibitors that aid to control blood glucose levels in type 2 diabetes mellitus. An assessment of efficacy was performed by measuring the post - treatment glycosylated hemoglobin (HbA1c) levels. This was a Single - centre, Retrospective, Comparative Clinical Study that recruited a total number of 340 subjects fulfilling study criteria. Subjects who were on stable doses of metformin and with HbA1c values between ?8% to
Keywords: Retrospective, Type 2 Diabetes mellitus, Vildagliptin, Sitagliptin, Dipeptidyl peptidase - 4 inhibitor
How to Cite?: Dr. K. Vamsi Krishna, Dr Sanjeet Kumar Jaiswal, Dr Subodh Jain, Dr Syed Haroon Iqubal, Dr. Sona Warrier, Dr. Ashish Prasad, Dr. Ashish Birla, Mr. Vinod More, Dr. Ravindra Mote, "A Comparative Retrospective Study of Vildagliptin 100mg SR OD and Sitagliptin 100 mg in Subjects with Type 2 Diabetes Mellitus", Volume 12 Issue 8, August 2023, International Journal of Science and Research (IJSR), Pages: 2350-2355, https://www.ijsr.net/getabstract.php?paperid=SR23822112319, DOI: https://dx.doi.org/10.21275/SR23822112319